Table 2 Sensitivity analyses for the linear decision analytical model in the United Kingdom, Germany, France and Italy

United Kingdom

 Hospitalisation cost

Reduction 10%

Increase 10%

 Exclude main sunitinib adverse event

Lymphopaenia

Thrombocytopaenia

Both adverse events

 Exclude main bevacizumab + IFN adverse event

Proteinuria

Fatigue and asthaenia

Both adverse events

 Germany

5% increase ambulatory treatment

 Value of points

Three points

Six points

 Hospitalisation cost

Reduction 10%

Increase 10%

 Exclude main sunitinib adverse event

Neutropaenia

Lymphopaenia

Both adverse events

 Exclude main bevacizumab + IFN adverse event

Fatigue and asthaenia

GI perforation

Both adverse events

 France

 Hospitalisation cost

Reduction 10%

Increase 10%

 Exclude main sunitinib adverse event

Anaemia

Neutropaenia

Both adverse events

 Exclude main bevacizumab + IFN adverse event

Fatigue/asthaenia

Anaemia

Both adverse events

 Italy^a

 Hospitalisation cost

Reduction 10%

Increase 10%

 Exclude main sunitinib adverse event

Lymphopaenia

Hypertension

Both adverse events

 Exclude main bevacizumab + IFN adverse event

Venous thrombosis

Fatigue/asthaenia

Both adverse events